JPS59175440A - グラム陰性バクテリアのワクチン - Google Patents

グラム陰性バクテリアのワクチン

Info

Publication number: JPS59175440A
Authority: JP; Japan
Prior art keywords: gram; detoxified; polysaccharide; protein; pseudomonas aeruginosa
Prior art date: 1983-03-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP59045764A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0577657B2 (2

Inventor

グレイス・シ−・ツエイ

マイケル・エス・コリンズ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Corp

Original Assignee

Miles Laboratories Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-03-14

Filing date

1984-03-12

Publication date

1984-10-04

1984-03-12 Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc

1984-10-04 Publication of JPS59175440A publication Critical patent/JPS59175440A/ja

1993-10-27 Publication of JPH0577657B2 publication Critical patent/JPH0577657B2/ja

Status Granted legal-status Critical Current

Links

229960001212 bacterial vaccine Drugs 0.000 title 1
150000004676 glycans Chemical class 0.000 claims abstract description 63
229920001282 polysaccharide Polymers 0.000 claims abstract description 63
239000005017 polysaccharide Substances 0.000 claims abstract description 63
102000004169 proteins and genes Human genes 0.000 claims abstract description 49
108090000623 proteins and genes Proteins 0.000 claims abstract description 49
239000000203 mixture Substances 0.000 claims abstract description 47
239000002158 endotoxin Substances 0.000 claims abstract description 42
241000894006 Bacteria Species 0.000 claims abstract description 38
229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 34
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims abstract description 19
241000589517 Pseudomonas aeruginosa Species 0.000 claims description 32
238000000034 method Methods 0.000 claims description 27
208000015181 infectious disease Diseases 0.000 claims description 18
108010045362 Serum Globulins Proteins 0.000 claims description 14
102000005686 Serum Globulins Human genes 0.000 claims description 14
125000004432 carbon atom Chemical group C* 0.000 claims description 12
230000001900 immune effect Effects 0.000 claims description 11
210000004369 blood Anatomy 0.000 claims description 9
239000008280 blood Substances 0.000 claims description 9
230000000521 hyperimmunizing effect Effects 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 6
244000005700 microbiome Species 0.000 claims description 5
125000003277 amino group Chemical group 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
231100000419 toxicity Toxicity 0.000 claims description 4
230000001988 toxicity Effects 0.000 claims description 4
239000012752 auxiliary agent Substances 0.000 claims description 3
230000028993 immune response Effects 0.000 claims description 3
239000003053 toxin Substances 0.000 claims description 3
231100000765 toxin Toxicity 0.000 claims description 3
108700012359 toxins Proteins 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims description 2
230000001590 oxidative effect Effects 0.000 claims 1
125000003172 aldehyde group Chemical group 0.000 abstract description 10
230000003053 immunization Effects 0.000 abstract description 7
229940124452 immunizing agent Drugs 0.000 abstract description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
230000003647 oxidation Effects 0.000 abstract 1
238000007254 oxidation reaction Methods 0.000 abstract 1
150000002632 lipids Chemical class 0.000 description 18
241000699670 Mus sp. Species 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 11
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
239000000427 antigen Substances 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 7
229960005486 vaccine Drugs 0.000 description 7
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
238000002523 gelfiltration Methods 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
-1 periodate ions Chemical class 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000000108 ultra-filtration Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
108010077805 Bacterial Proteins Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
239000003513 alkali Substances 0.000 description 4
210000004423 amoeboid cell Anatomy 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
229940001442 combination vaccine Drugs 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
239000006166 lysate Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
241000894007 species Species 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
208000032536 Pseudomonas Infections Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
238000009739 binding Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
125000002843 carboxylic acid group Chemical group 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
230000007893 endotoxin activity Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
238000002390 rotary evaporation Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
241001529572 Chaceon affinis Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
231100000111 LD50 Toxicity 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010067372 Pancreatic elastase Proteins 0.000 description 2
102000016387 Pancreatic elastase Human genes 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108010059712 Pronase Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
231100000956 nontoxicity Toxicity 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
238000000053 physical method Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003809 water extraction Methods 0.000 description 2
MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
NGZUCVGMNQGGNA-UHFFFAOYSA-N 7-[5-(2-acetamidoethyl)-2-hydroxyphenyl]-3,5,6,8-tetrahydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid 7-[5-(2-amino-2-carboxyethyl)-2-hydroxyphenyl]-3,5,6,8-tetrahydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid 3,5,6,8-tetrahydroxy-7-[2-hydroxy-5-(2-hydroxyethyl)phenyl]-9,10-dioxoanthracene-1,2-dicarboxylic acid 3,6,8-trihydroxy-1-methyl-9,10-dioxoanthracene-2-carboxylic acid Chemical compound Cc1c(C(O)=O)c(O)cc2C(=O)c3cc(O)cc(O)c3C(=O)c12.OCCc1ccc(O)c(c1)-c1c(O)c(O)c2C(=O)c3cc(O)c(C(O)=O)c(C(O)=O)c3C(=O)c2c1O.CC(=O)NCCc1ccc(O)c(c1)-c1c(O)c(O)c2C(=O)c3cc(O)c(C(O)=O)c(C(O)=O)c3C(=O)c2c1O.NC(Cc1ccc(O)c(c1)-c1c(O)c(O)c2C(=O)c3cc(O)c(C(O)=O)c(C(O)=O)c3C(=O)c2c1O)C(O)=O NGZUCVGMNQGGNA-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001002658 Bellamya aeruginosa Species 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
241000334216 Proteus sp. Species 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
241001417495 Serranidae Species 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000256215 Spongomorpha aeruginosa Species 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000009056 active transport Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000010908 decantation Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000002346 endotoxic effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007236 host immunity Effects 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000013627 low molecular weight specie Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000693 micelle Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP59045764A 1983-03-14 1984-03-12 グラム陰性バクテリアのワクチン Granted JPS59175440A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/475,415 US4663160A (en)	1983-03-14	1983-03-14	Vaccines for gram-negative bacteria
US475415		1983-03-14

Publications (2)

Publication Number	Publication Date
JPS59175440A true JPS59175440A (ja)	1984-10-04
JPH0577657B2 JPH0577657B2 (2)	1993-10-27

Family

ID=23887470

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59045764A Granted JPS59175440A (ja)	1983-03-14	1984-03-12	グラム陰性バクテリアのワクチン

Country Status (5)

Country	Link
US (1)	US4663160A (2)
EP (2)	EP0118831B1 (2)
JP (1)	JPS59175440A (2)
AT (1)	ATE44238T1 (2)
DE (1)	DE3478789D1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986005396A1 (fr) *	1985-03-11	1986-09-25	Teijin Limited	ANTIGENE E87Ag DU PSEUDOMONAS AERUGINOSE, ANTICORPS MONOCLONAL CONTRE CET ANTIGENE ET HYBRIDOME
JPS6289632A (ja) *	1985-09-27	1987-04-24	シユウアイツエリツシエス・ゼル−ム−ウント・イムプフインステイトウト・ウント・インステイトウト・ツ−ル・エルフオルシユング・デル・インフエクツイオンスクランクハイテン	グラム陰性菌による感染に対する接合ワクチン及びその使用法

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5360897A (en) *	1981-08-31	1994-11-01	The University Of Rochester	Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
IT1187753B (it) *	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
US4755381A (en) *	1986-03-27	1988-07-05	Swiss Serum And Vaccine Institute Berne	Klebsiella capsular polysaccharide vaccine
US4789544A (en) *	1986-05-23	1988-12-06	Midcon Labs. Inc.	Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5043158A (en) *	1987-08-21	1991-08-27	Chembiomed, Ltd.	Immunogenic compositions containing ordered carriers
DE3727987A1 (de) *	1987-08-21	1989-03-02	Sleytr Uwe B	Pharmazeutische struktur
US5063054A (en) *	1988-04-18	1991-11-05	Joseph Chang	Microbial products used for treatment of hepatitis
NZ239643A (en) *	1990-09-17	1996-05-28	North American Vaccine Inc	Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) *	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
FR2682388B1 (fr) *	1991-10-10	1995-06-09	Pasteur Merieux Serums Vacc	Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
EP0623026A1 (en) *	1992-01-16	1994-11-09	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
US5554730A (en) *	1993-03-09	1996-09-10	Middlesex Sciences, Inc.	Method and kit for making a polysaccharide-protein conjugate
US5866132A (en) *	1995-06-07	1999-02-02	Alberta Research Council	Immunogenic oligosaccharide compositions
US5695768A (en) *	1995-06-07	1997-12-09	Alberta Research Council	Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US6329925B1 (en)	1999-11-24	2001-12-11	Donnelly Corporation	Rearview mirror assembly with added feature modular display
US6693517B2 (en)	2000-04-21	2004-02-17	Donnelly Corporation	Vehicle mirror assembly communicating wirelessly with vehicle accessories and occupants
US6477464B2 (en)	2000-03-09	2002-11-05	Donnelly Corporation	Complete mirror-based global-positioning system (GPS) navigation solution
EP1096952B1 (en)	1998-07-15	2008-05-21	The Brigham And Women's Hospital, Inc.	Polysaccharide vaccine for staphylococcal infections
JP2004505885A (ja) *	1998-08-19	2004-02-26	ノース　アメリカン　ワクチン，　インコーポレイテッド	Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
US7370983B2 (en)	2000-03-02	2008-05-13	Donnelly Corporation	Interior mirror assembly with display
US7167796B2 (en)	2000-03-09	2007-01-23	Donnelly Corporation	Vehicle navigation system for use with a telematics system
US7255451B2 (en)	2002-09-20	2007-08-14	Donnelly Corporation	Electro-optic mirror cell
WO2002062623A2 (en)	2001-01-23	2002-08-15	Donnelly Corporation	Improved vehicular lighting system for a mirror assembly
US7581859B2 (en)	2005-09-14	2009-09-01	Donnelly Corp.	Display device for exterior rearview mirror
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
AU2002309259A1 (en) *	2002-05-09	2003-11-11	Massimo Porro	Improved polysaccharide and glycoconjugate vaccines_____________
US7310177B2 (en)	2002-09-20	2007-12-18	Donnelly Corporation	Electro-optic reflective element assembly
HUE031886T2 (en)	2002-10-11	2017-08-28	Glaxosmithkline Biologicals Sa	Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
ES2461350T3 (es)	2003-01-30	2014-05-19	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
CN103357002A (zh)	2003-10-02	2013-10-23	诺华疫苗和诊断有限公司	多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
WO2005044861A1 (en) *	2003-10-31	2005-05-19	Wyeth Holdings Corporation	Polysaccharides of helicobacter pylori
WO2005072778A2 (en) *	2004-01-29	2005-08-11	Biosynexus, Inc.	Use of amino-oxy functional groups in the preparation of vaccines conjugates
GB0406013D0 (en)	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
GB0408977D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Immunising against meningococcal serogroup Y using proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
ATE512670T1 (de)	2004-04-30	2011-07-15	Novartis Vaccines & Diagnostic	Meningokokken-konjugat-impfung
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0411387D0 (en)	2004-05-21	2004-06-23	Chiron Srl	Analysis of saccharide length
US8246993B2 (en) *	2004-06-10	2012-08-21	Cytogel Pharma, Llc	Advantageous hydrogel composition
GB0413868D0 (en)	2004-06-21	2004-07-21	Chiron Srl	Dimensional anlaysis of saccharide conjugates
US20060013886A1 (en) *	2004-06-28	2006-01-19	Daqing Wu	Injectable microspheres
US20060062779A1 (en)	2004-09-21	2006-03-23	The Brigham And Women's Hospital, Inc.	Methods and compositions relating to mannuronic acid specific binding peptides
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
PL2004225T3 (pl)	2006-03-22	2012-09-28	Novartis Ag	Schematy immunizacji koniugatami meningokokowymi
GB0605757D0 (en)	2006-03-22	2006-05-03	Chiron Srl	Separation of conjugated and unconjugated components
GB0612854D0 (en)	2006-06-28	2006-08-09	Novartis Ag	Saccharide analysis
US8945582B2 (en)	2006-09-07	2015-02-03	Glaxosmithkline Biologicals S.A.	Vaccine
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
BRPI0810778A2 (pt)	2007-05-02	2011-09-13	Glaxosmithkline Biolog Sa	kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
GB0713880D0 (en) *	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
US8017898B2 (en)	2007-08-17	2011-09-13	Magna Electronics Inc.	Vehicular imaging system in an automatic headlamp control system
US8446470B2 (en)	2007-10-04	2013-05-21	Magna Electronics, Inc.	Combined RGB and IR imaging sensor
WO2009050586A1 (en)	2007-10-19	2009-04-23	Novartis Ag	Meningococcal vaccine formulations
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN102356089B (zh)	2008-02-21	2014-02-19	诺华股份有限公司	脑膜炎球菌fHBP多肽
SI2349520T1 (sl)	2008-10-27	2016-08-31	Glaxosmithkline Biologicals S.A.	Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
JP2012512240A (ja)	2008-12-17	2012-05-31	ノバルティスアーゲー	ヘモグロビン受容体を含む髄膜炎菌ワクチン
EP3017826A1 (en)	2009-03-24	2016-05-11	Novartis AG	Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
HUE049695T2 (hu)	2009-03-24	2020-10-28	Glaxosmithkline Biologicals Sa	Adjuváló H meningococcus faktort kötõ fehérje
MX2011010735A (es)	2009-04-14	2012-01-25	Novartis Ag	Composiciones para inmunizacion contra staphylococcus aureus.
WO2011017101A2 (en)	2009-07-27	2011-02-10	Fina Biosolutions, Llc	Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
US20110076300A1 (en)	2009-08-27	2011-03-31	Mariagrazia Pizza	Hybrid Polypeptides Including Meningococcal fHBP Sequences
CN102695523A (zh)	2009-09-10	2012-09-26	诺华有限公司	针对呼吸道疾病的组合疫苗
CN102724988B (zh)	2009-09-30	2014-09-10	诺华股份有限公司	脑膜炎球菌fHBP多肽的表达
US8974799B2 (en)	2009-09-30	2015-03-10	Novartis Ag	Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CA2779816A1 (en)	2009-10-27	2011-05-05	Novartis Ag	Modified meningococcal fhbp polypeptides
BR112012010223A2 (pt)	2009-10-30	2016-12-06	Novartis Ag	purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
MX2012006961A (es)	2009-12-17	2012-10-03	Fina Biosolutions Llc	Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
JP5781542B2 (ja)	2009-12-30	2015-09-24	ノバルティスアーゲー	Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
WO2011146922A2 (en)	2010-05-21	2011-11-24	Cytogel Pharma, Llc	Materials and methods for treatment of inflammation
CA2803239A1 (en)	2010-06-25	2011-12-29	Novartis Ag	Combinations of meningococcal factor h binding proteins
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en)	2010-12-24	2012-06-28	Novartis Ag	Compounds
WO2012117377A1 (en)	2011-03-02	2012-09-07	Novartis Ag	Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en)	2011-08-30	2011-10-12	Novartis Ag	Immunogenic proteins and compositions
EP2776069A1 (en)	2011-11-07	2014-09-17	Novartis AG	Carrier molecule comprising a spr0096 and a spr2021 antigen
ES2647882T3 (es)	2011-12-06	2017-12-27	Valneva Austria Gmbh	Compuestos de aluminio para su uso en productos terapéuticos y vacunas
GB201121301D0 (en)	2011-12-12	2012-01-25	Novartis Ag	Method
EP2797624A1 (en)	2011-12-29	2014-11-05	Novartis AG	Adjuvanted combinations of meningococcal factor h binding proteins
JP2015510872A (ja)	2012-03-07	2015-04-13	ノバルティスアーゲー	Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
CN104159603A (zh)	2012-03-08	2014-11-19	诺华股份有限公司	带有tlr4激动剂的联合疫苗
EP2872535A1 (en)	2012-07-16	2015-05-20	Pfizer Inc.	Saccharides and uses thereof
US9526776B2 (en)	2012-09-06	2016-12-27	Glaxosmithkline Biologicals Sa	Combination vaccines with serogroup B meningococcus and D/T/P
WO2014053521A2 (en)	2012-10-02	2014-04-10	Novartis Ag	Nonlinear saccharide conjugates
US20150273036A1 (en)	2012-10-12	2015-10-01	Glaxosmithkline Biologicals Sa	Non-cross-linked acellular pertussis antigens for use in combination vaccines
RS56886B1 (sr)	2012-11-30	2018-04-30	Glaxosmithkline Biologicals Sa	Antigeni pseudomonasa i kombinacije antigena
JP6411378B2 (ja)	2013-02-01	2018-10-24	グラクソスミスクラインバイオロジカルズソシエテアノニム	Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
US9943583B2 (en) *	2013-12-03	2018-04-17	Universität Zürich	Proline-rich peptides protective against S. pneumoniae
JP6786394B2 (ja)	2014-02-28	2020-11-18	グラクソスミスクラインバイオロジカルズソシエテアノニム	改変髄膜炎菌ｆＨｂｐポリペプチド
EP3034516A1 (en)	2014-12-19	2016-06-22	Novartis AG	Purification of streptococcal capsular polysaccharide
US12161707B2 (en)	2016-09-02	2024-12-10	Glaxosmithkline Biologicals Sa	Vaccines for Neisseria gonorrhoeae
EP3551668A1 (en)	2016-12-06	2019-10-16	GlaxoSmithKline Biologicals S.A.	Purification process for capsular polysaccharide
WO2018237221A1 (en) *	2017-06-23	2018-12-27	Nosocomial Vaccine Corporation	IMMUNOGENIC COMPOSITIONS
US10975121B2 (en)	2017-06-24	2021-04-13	Cytogel Pharma, Llc	Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
EP3607967A1 (en)	2018-08-09	2020-02-12	GlaxoSmithKline Biologicals S.A.	Modified meningococcal fhbp polypeptides
EP3799884A1 (en)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
GB202013262D0 (en)	2020-08-25	2020-10-07	Glaxosmithkline Biologicals Sa	Vaccine Composition
GB202208093D0 (en)	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition
GB202208089D0 (en)	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH396316A (de) *	1960-07-12	1965-07-31	Wander Ag Dr A	Verfahren zur Herstellung von Impfstoffen
US3987164A (en) *	1970-10-20	1976-10-19	Yuzuru Homma	Method for prevention of pseudomonas aeruginosa infections
US4185090A (en) *	1972-02-02	1980-01-22	Abbott Laboratories	Chemically modified endotoxin immunizing agent
US4110432A (en) *	1974-06-04	1978-08-29	Burroughs Wellcome Co.	Conjugates of prostaglandins, analogs, formulations and their use
JPS51106714A (2) *	1975-03-12	1976-09-21	Tokyo Daigaku
JPS5296729A (en) *	1976-02-05	1977-08-13	Shionogi & Co Ltd	Mixed vaccin for cyanomycosis
FR2460139A1 (fr) *	1979-06-29	1981-01-23	Pasteur Institut	Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
JPS5639022A (en) *	1979-09-05	1981-04-14	Hayashibara Biochem Lab Inc	Preparation of vaccine
US4285936A (en) *	1979-12-10	1981-08-25	The United States Of America As Represented By The Secretary Of The Army	Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
US4356170A (en) *	1981-05-27	1982-10-26	Canadian Patents & Development Ltd.	Immunogenic polysaccharide-protein conjugates
US4459286A (en) *	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine

1983
- 1983-03-14 US US06/475,415 patent/US4663160A/en not_active Expired - Fee Related
1984
- 1984-02-29 AT AT84102119T patent/ATE44238T1/de not_active IP Right Cessation
- 1984-02-29 EP EP84102119A patent/EP0118831B1/en not_active Expired
- 1984-02-29 EP EP88105929A patent/EP0306607A1/en not_active Withdrawn
- 1984-02-29 DE DE8484102119T patent/DE3478789D1/de not_active Expired
- 1984-03-12 JP JP59045764A patent/JPS59175440A/ja active Granted

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986005396A1 (fr) *	1985-03-11	1986-09-25	Teijin Limited	ANTIGENE E87Ag DU PSEUDOMONAS AERUGINOSE, ANTICORPS MONOCLONAL CONTRE CET ANTIGENE ET HYBRIDOME
JPS6289632A (ja) *	1985-09-27	1987-04-24	シユウアイツエリツシエス・ゼル−ム−ウント・イムプフインステイトウト・ウント・インステイトウト・ツ−ル・エルフオルシユング・デル・インフエクツイオンスクランクハイテン	グラム陰性菌による感染に対する接合ワクチン及びその使用法

Also Published As

Publication number	Publication date
EP0118831A3 (en)	1986-12-10
DE3478789D1 (en)	1989-08-03
ATE44238T1 (de)	1989-07-15
EP0118831B1 (en)	1989-06-28
US4663160A (en)	1987-05-05
EP0306607A1 (en)	1989-03-15
JPH0577657B2 (2)	1993-10-27
EP0118831A2 (en)	1984-09-19

Publication	Publication Date	Title
JPS59175440A (ja)	1984-10-04	グラム陰性バクテリアのワクチン
US4460575A (en)	1984-07-17	Vaccinal complex containing a specific antigen and vaccine containing it
US4372945A (en)	1983-02-08	Antigen compounds
EP0549617B1 (en)	1996-03-27	Improved vaccine compositions
US4271147A (en)	1981-06-02	Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
Frasch et al.	1978	Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
US4693891A (en)	1987-09-15	Vaccine for Pseudomonas aeruginosa
JPS58162531A (ja)	1983-09-27	細菌莢膜由来の多糖類−蛋白質複合体の製法、その生成物およびそれを含有する免疫原組成物
JPS6289632A (ja)	1987-04-24	グラム陰性菌による感染に対する接合ワクチン及びその使用法
CA2406229C (en)	2010-09-07	Anti-sepsis conjugate vaccine
US4314993A (en)	1982-02-09	Immunogenic E. coli ST enterotoxin derivatives and compositions containing them
Relyveld et al.	1983	[3] Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens, and cells
Michel et al.	1978	Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans
US4285930A (en)	1981-08-25	Antigens comprising immunostimulant adjuvants and their use in immunotherapy
US4242270A (en)	1980-12-30	Process for separating lipids from endotoxins
CA2128212A1 (en)	1993-07-22	Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
RU2260053C2 (ru)	2005-09-10	Способ выделения биологически активной фракции (баф), содержащей s-липополисахариды (s-лпс) из грамотрицательных бактерий, баф для лечения и профилактики заболеваний, вызываемых грамотрицательными бактериями, производящими эндотоксичные s-лпс, фармацевтическая композиция, способы индукции протективного иммунитета и улучшения состояния пациента при состояниях, требующих повышения иммунного статуса
JP7311103B2 (ja)	2023-07-19	ワクチン
RU2407792C1 (ru)	2010-12-27	СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ
RU2412197C2 (ru)	2011-02-20	Полимерный фрагмент пептидогликана клеточной стенки грамотрицательных бактерий, способ его получения и его применение в качестве иммуностимулятора
Keppie et al.	1960	The Chemical Basis of the Virulence of Pasteurella pestis: III. An Immunogenic Product Obtained from Past. pestis which Protects both Guinea-pigs and Mice
CA3081769C (en)	2025-09-16	A vaccine comprising a delipidated c. burnetii polysaccharide
GB2144129A (en)	1985-02-27	Antigens as immunostimulant adjuvants
JPS5888319A (ja)	1983-05-26	ステリン結合抗原性蛋白質
GB2104527A (en)	1983-03-09	Antigens as immunostimulant adjuvants

JPS59175440A - グラム陰性バクテリアのワクチン - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=23887470

Family Applications (1)

Country Status (5)

Cited By (2)

Families Citing this family (107)

Family Cites Families (11)

Cited By (2)

Also Published As

Similar Documents